Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease.
作者信息
Chien Yin-Hsiu, Lee Ni-Chung, Tsai Fu-Jen, Chao May-Chin, Hwu Wuh-Liang
出版信息
Mol Genet Metab. 2010 Sep;101(1):90-1. doi: 10.1016/j.ymgme.2010.05.016. Epub 2010 Jun 9.
PMID:20580583
Abstract
摘要
相似文献
1
Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease.戈谢病患者伊米苷酶剂量减少会导致壳三糖苷酶活性立即升高。
Mol Genet Metab. 2010 Sep;101(1):90-1. doi: 10.1016/j.ymgme.2010.05.016. Epub 2010 Jun 9.
2
Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.戈谢病患者停用替代酶（葡糖脑苷脂酶）治疗后血清壳三糖苷酶活性的变化
Clin Biochem. 2000 Mar;33(2):147-9. doi: 10.1016/s0009-9120(99)00098-3.
3
The effect of enzyme therapy in a patient with Gaucher disease type III.酶疗法对一名Ⅲ型戈谢病患者的疗效。
J Inherit Metab Dis. 1996;19(5):703-4. doi: 10.1007/BF01799852.
4
Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.在初始酶替代治疗期间，MIP-1β和壳三糖苷酶呈现不同的剂量依赖性校正。
J Inherit Metab Dis. 2009 Apr;32(2):274-9. doi: 10.1007/s10545-009-1064-5. Epub 2009 Mar 4.
5
[Gaucher disease and chitotriosidase].[戈谢病与壳三糖苷酶]
Rev Med Interne. 2006 Mar;27 Suppl 1:S26-9. doi: 10.1016/s0248-8663(06)80008-1.
6
Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.伊米苷酶供应短缺对3型戈谢病诺尔伯顿患者临床和实验室参数的影响。
Arch Immunol Ther Exp (Warsz). 2015 Feb;63(1):65-71. doi: 10.1007/s00005-014-0308-8. Epub 2014 Sep 10.
7
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.用他利糖酶α进行酶替代疗法：对先前接受过伊米苷酶治疗的戈谢病成年患者的36个月安全性和疗效结果。
Am J Hematol. 2016 Jul;91(7):661-5. doi: 10.1002/ajh.24399. Epub 2016 May 18.
8
Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT).接受酶替代疗法（ERT）的戈谢病患者的血清壳三糖苷酶活性。
Clin Biochem. 1998 Jul;31(5):417-20. doi: 10.1016/s0009-9120(98)00030-7.
9
Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.从低剂量伊米苷酶转换为威拉苷酶治疗 1 型戈谢病的效果：临床和生化结局。
Haematologica. 2012 Dec;97(12):1850-4. doi: 10.3324/haematol.2011.059071. Epub 2012 Jul 6.
10
Low-dose versus high-dose therapy for Gaucher disease: Goals and markers.戈谢病的低剂量与高剂量疗法：目标与标志物
Blood. 2007 Jan 1;109(1):387; author reply 387-8. doi: 10.1182/blood-2006-07-033233.
引用本文的文献
1
Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.伊米苷酶供应受限对法国1型戈谢病患者治疗管理及病程的影响
Orphanet J Rare Dis. 2015 May 13;10:62. doi: 10.1186/s13023-015-0275-0.
Zotero 插件